Cidara Therapeutics, Inc. (NASDAQ:CDTX) had its target price boosted by HC Wainwright from $14.00 to $16.00 in a research note issued to investors on Thursday morning. HC Wainwright currently has a buy rating on the biotechnology company’s stock.
Other equities research analysts have also recently issued research reports about the company. WBB Securities raised Cidara Therapeutics from a sell rating to a hold rating in a research note on Friday, August 11th. Zacks Investment Research raised Cidara Therapeutics from a hold rating to a buy rating and set a $8.75 price target for the company in a research note on Wednesday, October 25th. Cantor Fitzgerald set a $15.00 price target on Cidara Therapeutics and gave the company a buy rating in a research note on Thursday, August 10th. Finally, ValuEngine raised Cidara Therapeutics from a strong sell rating to a sell rating in a research note on Friday, July 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Cidara Therapeutics has an average rating of Buy and a consensus price target of $13.39.
Cidara Therapeutics (NASDAQ CDTX) traded up $0.15 during trading on Thursday, reaching $7.80. The company’s stock had a trading volume of 54,800 shares, compared to its average volume of 106,390. The company has a quick ratio of 7.69, a current ratio of 7.69 and a debt-to-equity ratio of 0.16. Cidara Therapeutics has a 1 year low of $5.60 and a 1 year high of $11.85.
Cidara Therapeutics (NASDAQ:CDTX) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.21. research analysts anticipate that Cidara Therapeutics will post -3.42 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This article was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/11/13/hc-wainwright-boosts-cidara-therapeutics-inc-cdtx-price-target-to-16-00.html.
In other Cidara Therapeutics news, CEO Jeffrey Stein bought 7,350 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was acquired at an average price of $6.79 per share, with a total value of $49,906.50. Following the completion of the purchase, the chief executive officer now directly owns 51,851 shares of the company’s stock, valued at approximately $352,068.29. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 18.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CDTX. Trexquant Investment LP acquired a new stake in Cidara Therapeutics during the second quarter worth approximately $110,000. Citadel Advisors LLC acquired a new stake in Cidara Therapeutics during the second quarter worth approximately $129,000. Raymond James Financial Services Advisors Inc. acquired a new stake in Cidara Therapeutics during the second quarter worth approximately $131,000. OxFORD Asset Management LLP grew its stake in Cidara Therapeutics by 69.1% during the third quarter. OxFORD Asset Management LLP now owns 22,181 shares of the biotechnology company’s stock worth $187,000 after purchasing an additional 9,065 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in Cidara Therapeutics by 455.6% during the first quarter. JPMorgan Chase & Co. now owns 25,639 shares of the biotechnology company’s stock worth $200,000 after purchasing an additional 21,024 shares during the period. 66.11% of the stock is owned by institutional investors and hedge funds.
About Cidara Therapeutics
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.